{"DataElement":{"publicId":"3269842","version":"1","preferredName":"Retinoid X Receptors Testing Outcome Laboratory Procedure Outcome Percentage Value","preferredDefinition":"Percentage value to represent the result of retinoid X receptors (RXR) testing.","longName":"RXR_TST_PCT_VAL","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3269837","version":"1","preferredName":"Retinoid X Receptors Testing Outcome","preferredDefinition":"Human nuclear Retinoid X Receptors RXRA, RXRB, and RXRG (NR2/RXR Family) are transcriptional regulators composed of N-terminal modulating domain, DNA-binding domain (AGGTCA response elements), and C-terminal 9-cis RA-binding domain. RXR homodimers and RXR/RAR heterodimers mediate distinct retinoic acid response pathways. RXRs also interact with TH- and vitamin D receptors, and with NCOA3, NCOA6, PML, and PPARG coactivators; and mediate RA biological effects by binding to specific target gene promoters and inducing target gene transcription. RXRs/LXRs and RXRs/FXR may mediate cholesterol homeostasis, by governing cholesterol transport from peripheral cells, inhibiting cholesterol absorption in the small intestine, and repressing bile acid synthesis through upregulation of ABC1 and repression of CYP7A1 expression. (NCI)_A procedure for critical evaluation._a phenomenon that follows and is caused by some previous phenomenon.","longName":"RXR_TST_OUTC","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3269818","version":"1","preferredName":"Retinoid X Receptors","preferredDefinition":"Human nuclear Retinoid X Receptors RXRA, RXRB, and RXRG (NR2/RXR Family) are transcriptional regulators composed of N-terminal modulating domain, DNA-binding domain (AGGTCA response elements), and C-terminal 9-cis RA-binding domain. RXR homodimers and RXR/RAR heterodimers mediate distinct retinoic acid response pathways. RXRs also interact with TH- and vitamin D receptors, and with NCOA3, NCOA6, PML, and PPARG coactivators; and mediate RA biological effects by binding to specific target gene promoters and inducing target gene transcription. RXRs/LXRs and RXRs/FXR may mediate cholesterol homeostasis, by governing cholesterol transport from peripheral cells, inhibiting cholesterol absorption in the small intestine, and repressing bile acid synthesis through upregulation of ABC1 and repression of CYP7A1 expression. (NCI)","longName":"C0140283","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retinoid X Receptors","conceptCode":"C0140283","definition":"Human nuclear Retinoid X Receptors RXRA, RXRB, and RXRG (NR2/RXR Family) are transcriptional regulators composed of N-terminal modulating domain, DNA-binding domain (AGGTCA response elements), and C-terminal 9-cis RA-binding domain. RXR homodimers and RXR/RAR heterodimers mediate distinct retinoic acid response pathways. RXRs also interact with TH- and vitamin D receptors, and with NCOA3, NCOA6, PML, and PPARG coactivators; and mediate RA biological effects by binding to specific target gene promoters and inducing target gene transcription. RXRs/LXRs and RXRs/FXR may mediate cholesterol homeostasis, by governing cholesterol transport from peripheral cells, inhibiting cholesterol absorption in the small intestine, and repressing bile acid synthesis through upregulation of ABC1 and repression of CYP7A1 expression. (NCI)","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC46B303-421E-EC24-E040-BB89AD431A2A","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-06","modifiedBy":"ONEDATA","dateModified":"2011-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3269835","version":"1","preferredName":"Testing Outcome","preferredDefinition":"A procedure for critical evaluation.:a phenomenon that follows and is caused by some previous phenomenon.","longName":"C15336:CL025479","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Testing","conceptCode":"C15336","definition":"A procedure for critical evaluation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"CL025479","definition":"a phenomenon that follows and is caused by some previous phenomenon.","evsSource":"NCI_META_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC481ACE-A6F5-E171-E040-BB89AD4347AB","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-06","modifiedBy":"ONEDATA","dateModified":"2011-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC481ACE-A706-E171-E040-BB89AD4347AB","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-06","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3061015","version":"1","preferredName":"Laboratory Procedure Outcome Percentage Integer::0 Decimal Place Value","preferredDefinition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._The result of an action._A fraction or ratio with 100 understood as the denominator._A number with no fractional part, including the negative and positive numbers as well as zero.::0_An indication of the specific number of digits to be expected to the right of the decimal point in a line of numbers._A numerical quantity measured or assigned or computed.","longName":"3061015v1.0","context":"NHLBI","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","unitOfMeasure":"%","minLength":null,"maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":"0","format":"%","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3061014","version":"1","preferredName":"Laboratory Procedure Outcome Percentage Integer::0 Decimal Place Value","preferredDefinition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.:Outcome; a phenomenon that follows and is caused by some previous phenomenon.:Percentage; a fraction or ratio with 100 understood as the denominator.:A number with no fractional part.::0:An indication of the specific number of digits to be expected to the right of the decimal point in a line of numbers.:A numerical quantity measured or assigned or computed.","longName":"C25294:C20200:C25613:C45255::0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Percentage","conceptCode":"C25613","definition":"A fraction or ratio with 100 understood as the denominator.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Decimal Place","conceptCode":"C42646","definition":"An indication of the specific number of digits to be expected to the right of the decimal point in a line of numbers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Value","conceptCode":"C25712","definition":"A numerical quantity measured or assigned or computed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8446A1A4-4444-2A88-E040-BB89AD43255A","latestVersionIndicator":"Yes","beginDate":"2010-04-15","endDate":null,"createdBy":"WHITES","dateCreated":"2010-04-15","modifiedBy":"ONEDATA","dateModified":"2010-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8446A1A4-4455-2A88-E040-BB89AD43255A","latestVersionIndicator":"Yes","beginDate":"2010-04-15","endDate":null,"createdBy":"WHITES","dateCreated":"2010-04-15","modifiedBy":"NYCHM","dateModified":"2010-12-02","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2812571","version":"1","longName":"Lombardi Cancer Center","context":"NCIP"},{"publicId":"2812605","version":"1","longName":"Lombardi New CDEs","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Percent Expression (0-100%)","type":"Preferred Question Text","description":"Percent Expression (0-100%)","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC4797E5-10A5-B87C-E040-BB89AD430F29","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-06","modifiedBy":"REEVESD","dateModified":"2011-09-06","changeDescription":"Curated to support Lombardi Cancer Center clinical trial","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}